Innate Pharma Files 6-K Report with Press Release
Ticker: IPHYF · Form: 6-K · Filed: Mar 26, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Mar 26, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, press-release, foreign-issuer
TL;DR
Innate Pharma dropped a 6-K on 3/26 with a press release, standard foreign issuer filing.
AI Summary
On March 26, 2025, Innate Pharma SA filed a Form 6-K report. This filing includes a press release dated March 26, 2025, as Exhibit 99.1. The company is a foreign private issuer and files its annual reports under Form 20-F.
Why It Matters
This filing indicates ongoing reporting activity for Innate Pharma, providing investors with updated information through their press release.
Risk Assessment
Risk Level: low — This is a routine 6-K filing, primarily containing a press release and confirming standard reporting practices.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- March 26, 2025 (date) — Date of report and press release
- 001-39084 (other) — Commission File Number
- Form 20-F (other) — Annual report form
- Exhibit 99.1 (other) — Press Release
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to report information that Innate Pharma SA is required to disclose to the public, specifically including a press release dated March 26, 2025.
What is the Commission File Number for Innate Pharma SA?
The Commission File Number for Innate Pharma SA is 001-39084.
Does Innate Pharma SA file annual reports under Form 20-F or 40-F?
Innate Pharma SA files its annual reports under cover of Form 20-F.
What is the address of Innate Pharma SA's principal executive office?
The address of Innate Pharma SA's principal executive office is 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
What exhibit is included with this 6-K filing?
Exhibit 99.1, a Press Release dated March 26, 2025, is included with this 6-K filing.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 26, 2025 regarding Innate Pharma SA (IPHYF).